Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities

As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world. As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19. Several vaccines, including mRNA, vector-based vaccines, and inactivated vaccines, have been approved for emergency...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Autores principales: Wehbe, Zena, Wehbe, Maya, Iratni, Rabah, Pintus, Gianfranco, Zaraket, Hassan, Yassine, Hadi M., Eid, Ali H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043070/
https://ncbi.nlm.nih.gov/pubmed/33859652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.663586
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares